Avexa Says HIV Medicine Fights Virus in 48-Week Patient Study
By Simeon Bennett
March 12 (Bloomberg) -- Avexa Ltd., which is developing a medicine to treat drug-resistant HIV, said a study showed its experimental treatment reduced the virus to undetectable levels in 90 percent of patients after 48 weeks.
Avexa's drug, called apricitabine or ATC, also helped increase patients' CD4 cells, the infection-fighting cells that are destroyed by HIV, the Melbourne-based company said in a statement today. No resistance to the drug has been identified and no serious side effects were observed, the company said.
Avexa shares rose 1 cent, or 2.4 percent, to 42 cents on the Australian Stock Exchange at 12:48 p.m. Sydney time.
- Forums
- ASX - By Stock
- AVX
- bloomberg article
bloomberg article
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVX (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online